Direct Oral Anticoagulants (DOACs) Device Market Analysis: Opportunities, Innovations, and Growth Potential Through 2025–2034
The global Direct Oral Anticoagulants (DOACs) Device Market was valued at USD 31.67 billion in 2024, and it is projected to grow to USD 64.83 Billion by 2034. During the forecast period from 2025–2034, the market is estimated to rise at a compound annual growth rate (CAGR) of 7.44%. The rising incidence of thromboembolic conditions is accelerating the adoption of DOAC instruments, enabling data-driven, outcome-oriented clinical management across healthcare settings.
Market Definition
The Direct Oral Anticoagulants (DOACs) Device Market is experiencing steady growth due to rising cardiovascular disorders, increased adoption of DOAC therapies, and advancements in monitoring devices, driving demand for safer, more effective anticoagulation solutions across global healthcare settings.
Get access to the full report or request a complimentary sample for in-depth analysis:
Key Report Highlights
· The report highlights the key region that accounts for the highest revenue share in the global Direct Oral Anticoagulants (DOACs) Device Market.
· It identifies the leading country within this region that makes a significant contribution to the market’s overall performance.
· The report outlines the dominant segment that holds a major share of the market.
· It also emphasizes the fastest-growing segment projected to gain strong traction during the forecast period.
· Qualitative and quantitative market analysis have been used to provide an in-depth understanding of the market.
Market Overview: Key Figures at a Glance
· Market Value in 2024: USD 31.67 billion
· Projected Market Size in 2034: USD 64.83 Billion
· Anticipated CAGR (2025-2034): 7.44%
Market Key Players
The competitive landscape features a mix of long-standing companies and emerging contenders. Leading players are actively pursuing R&D initiatives and strategic moves to strengthen their market position. Notable participants include:
- Siemens Healthineers
- Abbott Laboratories
- Roche Diagnostics
- Sysmex Corporation
- Instrumentation Laboratory (Werfen)
- Nihon Kohden Corporation
- Diagnostica Stago
- Coag-Sense
- HemoSonics
- Sekisui Medical Co., Ltd.
- Grifols S.A.
- Helena Laboratories Corporation
Direct Oral Anticoagulants (DOACs) Device Market: Market Growth Drivers
- Rising Incidence of Thromboembolic Disorders: Increasing cases of conditions like deep vein thrombosis (DVT), atrial fibrillation, and pulmonary embolism are fueling demand for DOAC monitoring and management devices.
- Advancements in Drug Monitoring Technologies: Innovations in point-of-care testing and portable monitoring devices improve accuracy and patient compliance, driving market growth.
- Growing Geriatric Population: Aging populations are more susceptible to blood clotting disorders, leading to a higher need for anticoagulant therapies and related devices.
- Shift from Warfarin to DOACs: DOACs offer fewer dietary restrictions and no need for routine INR monitoring, encouraging broader adoption and the need for specialized support devices.
